Regulatory policies on medicines for psychiatric disorders: is Europe on target?
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 17267922.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The European Medicines Agency (EMEA) is the regulatory body that provides the institutions of the European Community with the best possible scientific advice on the quality, safety and efficacy of medicinal products. Drugs approved by the EMEA are automatically marketable in all the European member states. Since the beginning of the EMEA's activities a number of drugs acting on the central nervous system obtained marketing authorisation. This editorial highlights some aspects of the EMEA rules that may negatively affect the evaluation of medicines for psychiatric disorders.
Medical subject headings
- Drug Approval
- Government Agencies
- Mental Disorders
- Psychotropic Drugs